What do you think differentiates Novartis from competitors on the ground?
Mahesh Karande: I think given our diverse and broad portfolio, Novartis is uniquely well positioned to cover Africa’s disease burden. Additionally, there is a real commitment to invest and grow our presence in Africa from the highest levels of the organisation.
The scale and expertise within our company makes us well-positioned to tackle the diverse healthcare challenges in Africa. Our Pharmaceuticals Division is one of the largest pharmaceutical operations in the world, Sandoz offers one of the most extensive portfolios of generics and Alcon provide access to high-quality eye care. These divisions receive support from our global research organisation, the Novartis Institutes for BioMedical Research (NIBR), enabling us to bring innovative, high-quality and affordable medicine and therapies to patients.
We’re also focused on building African talent and developing differentiated business models that respond to economic realities. This approach will not only improve patient outcomes, but also expand our presence on the continent in a way that contributes to economic growth.
Finally, we know we have the backing of a global leader in healthcare, with strong, experienced people on the ground – people who have a real passion for Africa and its patients. Taken together, I think we have everything necessary to differentiate ourselves from the competition and make a real difference in the lives of patients across Africa.